pregnancy - MGH Center for Women's Mental Health

What’s Worse for Pregnancy: Bipolar Disorder or the Medications Used to Treat It?

In studies of pregnant women with unipolar depression, it has been shown that untreated psychiatric illness in the mother may have a negative impact on pregnancy outcomes, influencing the length of gestation and birthweight. There is far less data on pregnancy outcomes in women with bipolar disorder. A recent Swedish study analyzes pregnancy outcomes in treated and untreated women with bipolar disorder and attempts to distinguish between the effects of medication versus the effects of untreated psychiatric illness in the mother.

By Ruta Nonacs, MD PhD|2024-03-24T11:55:47-04:00February 5th, 2013|Bipolar Disorder, Mood Stabilizers, Outcomes, Pregnancy & Medications, Psychiatric Disorders During Pregnancy|Comments Off

Screening of Intimate Partner Violence Recommended for All Women of Reproductive Age

This is a topic we do not typically cover on our site, but it is clearly an important one. The U.S. Preventive Services Task Force (USPSTF) has updated its recommendations on screening for family and intimate partner violence (IPV). These guidelines, published in the Annals of Internal Medicine, recommend that all women of reproductive age be screened for intimate partner violence. The review provides some information on which screening instruments to use and reviews interventions to reduce the risk of IPV.

By MGH Center for Women's Mental Health|2015-08-06T13:36:28-04:00January 23rd, 2013|Diagnosis & Screening, General, Postpartum Psychiatric Disorders, Psychiatric Disorders During Pregnancy, PTSD and Stress Related Disorders|Comments Off

Father’s Psychological Health and Its Impact on Child Development

While much attention has focused on the impact of maternal psychiatric illness on the well-being of the child, less is known about the impact of psychiatric illness in the father. A large population-based study from Norway examines the association between symptoms of psychological distress in expectant fathers and socioemotional and behavioral outcomes in their children at 36 months of age.

By MGH Center for Women's Mental Health|2017-03-28T09:56:33-04:00January 22nd, 2013|Child Outcomes, Depressive Disorders, Outcomes, Postpartum Psychiatric Disorders|Comments Off

Hyperemesis Gravidarum and Depression: Which Comes First?

Most women have some nausea or vomiting, or "morning sickness", during the first trimester of pregnancy. Some women, however, have a more severe and persistent pattern of nausea and vomiting called hyperemesis gravidarum (HG). A new study demonstrates, not so surprisingly, that depression is more common in women suffering from HG.

By MGH Center for Women's Mental Health|2015-08-06T13:44:18-04:00January 15th, 2013|Depressive Disorders, Prevalence & Risk Factors, Psychiatric Disorders During Pregnancy|Comments Off

No Increase in Risk of Infant Mortality in Women Taking SSRIs During Pregnancy

While there has been a great deal of attention paid to the risks of exposure to antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), during pregnancy, there has been comparatively little information on the risk of stillbirth and infant mortality in this population. In a recent population-based cohort study utilizing data from all Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden), researchers assessed the risk of stillbirth and infant mortality associated with the use of SSRIs during pregnancy.

By MGH Center for Women's Mental Health|2015-08-06T13:48:29-04:00January 9th, 2013|Anti-Epileptic Drugs, Neonatal Symptoms, Outcomes, Pregnancy & Medications, Pregnancy Outcomes|Comments Off

Dr. Lee Cohen in Ob-Gyn News: Using SSRIs in Pregnancy

Over the last decade, attention in the medical literature has gathered logarithmically to focus on potentially efficacious treatments for perinatal depression. Studies of relevant databases, editorials, and various reviews have addressed the reproductive safety concerns of antidepressant treatments, particularly selective serotonin reuptake inhibitors (SSRIs) on one hand, and the impact of untreated maternal psychiatric illness on fetal and maternal well-being on the other.

By MGH Center for Women's Mental Health|2024-03-31T10:40:13-04:00December 13th, 2012|Antidepressants, ObGyn News, Outcomes, Pregnancy & Medications|Comments Off

SSRIs and Pregnancy: Putting the Risks and Benefits into Perspective

Prozac hit the market in 1988, the first selective serotonin reuptake inhibitor (SSRI) antidepressant approved by the FDA for the treatment of depression. Because it was safer and more tolerable than the antidepressants that preceded it, Prozac was soon the most commonly prescribed antidepressant in the United States.

By MGH Center for Women's Mental Health|2015-08-06T13:57:24-04:00December 6th, 2012|Antidepressants, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off

Duloxetine and Pregnancy: Preliminary Data

Duloxetine (sold in the United Sates under the brand name of Cymbalta) is a serotonin-norepinephrine reuptake inhibitor (SNRI) effective for major depressive disorder and generalized anxiety disorder (GAD). Although used fairly commonly in women of child-bearing age, information regarding its reproductive safety has been lacking.

By MGH Center for Women's Mental Health|2015-08-10T09:09:55-04:00November 30th, 2012|Antidepressants, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off

Exposure to Maternal Depression – Not Antidepressants – Predicts Worse Outcomes in Children

While data accumulated over the last 30 years suggest that certain antidepressants may be used with relative safety during pregnancy, our knowledge regarding the risks of prenatal exposure to psychotropic medications is incomplete. Because neuronal migration and differentiation occur throughout pregnancy and into the early years of life, development of the central nervous system (CNS) remains particularly vulnerable throughout pregnancy.

By MGH Center for Women's Mental Health|2015-08-10T14:09:05-04:00November 7th, 2012|Antidepressants, Outcomes, Pregnancy & Medications|Comments Off

Yet Another Study Investigating SSRIs and Their Impact on Neonatal Outcomes

In a recent retrospective cohort study, data collected from linked records from the Women's and Children's Health Network in South Australia were used to investigate neonatal outcomes in children exposed prenatally to selective serotonin reuptake inhibitors (SSRIs). Women were included in this study if they gave birth to a singleton, live-born infant between September 2000 and December 2008 (n = 33,965).

By MGH Center for Women's Mental Health|2015-08-12T11:38:25-04:00October 2nd, 2012|Antidepressants, Diagnosis & Screening, Neonatal Symptoms, Outcomes, Pregnancy & Medications|Comments Off